Group 1 - The company MiRXES-B (02629) has signed a memorandum of understanding with PT DIASTIKA BIOTEKINDO for collaboration in molecular diagnostic testing and related instruments for early detection and diagnosis of high-incidence and high-mortality cancers in Indonesia [1] - The memorandum is valid for 12 months from the date of signing [1] - The collaboration allows the company to leverage PT DIASTIKA BIOTEKINDO's existing channels to enter the Indonesian market with blood-based microRNA or multi-omics testing devices for high-incidence cancers such as gastric and lung cancer [1] Group 2 - The partnership enables the company to benefit from local policies in Indonesia, such as tax incentives for localization rates of 40% [1] - The collaboration aims to achieve regulatory flexibility under the ASEAN-centered medical device framework [1] - Indonesia is positioned as a pilot region for the company to replicate its business model in Southeast Asia, the Middle East, North Africa, and other regions with similar cancer profiles and healthcare structures [1]

Core Viewpoint - Company MiRXES-B has signed a memorandum of understanding with PT DIASTIKA BIOTEKINDO to collaborate on the registration and commercialization of molecular diagnostic tests for early detection and diagnosis of high-incidence and high-mortality cancers in Indonesia [1][2] Group 1: Collaboration Details - The memorandum is valid for 12 months and includes activities such as sales and distribution of new blood-based microRNA and multi-omics cancer early detection products in Indonesia [1] - The collaboration will involve joint development and clinical validation of projects for the registration of diagnostic devices, as well as training activities for Indonesian scientists and laboratory users [1] - The partnership will explore local manufacturing opportunities [1] Group 2: Market Potential and Strategy - PT DIASTIKA BIOTEKINDO operates a network of over 300 hospitals in Indonesia, providing immediate scale benefits for medical services, with 70% of these hospitals located in Java, serving 57% of the Indonesian population [2] - The collaboration allows the company to leverage existing distribution channels to enter the Indonesian market with blood-based cancer detection devices [2] - The partnership aims to utilize Indonesia's localization policies for tax incentives and regulatory flexibility, with plans to replicate the business model in Southeast Asia, the Middle East, North Africa, and other regions with similar cancer profiles and healthcare structures [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因 依賴該等內容而引致的任何損失承擔任何責任。 Mirxes Holding Company Limited （ 於 開 曼 群 島 註 冊 成 立 的 有 限 責 任 公 司 ） （股份代號：2629） 自願性公告 有關可能合作事項的諒解備忘錄 諒解備忘錄之主要條款如下： – 1 – 主要合作範圍 雙方同意在（其中包括）下列活動（統稱及各自稱為「合作活動」）方面開展真誠 合作： PT DIASTIKA BIOTEKINDO的資料 PT DIASTIKA BIOTEKINDO為一間根據印尼法律註冊成立之有限公司，主要於 印尼從事實驗室設備及試劑、製藥設備以及醫療設備及器械之批發業務。 PT DIASTIKA BIOTEKINDO的醫院網絡覆蓋逾300間醫院（其中70%位於爪哇， 居住57%印尼人口），實現即時規模效益醫療服務，而外島服務不足則蘊藏90% 尚未開發商機。 本公告乃由Mirxes Holding Company Limited（「本公司」， ...

本文源自智通财经网 国元国际认为，公司在基于miRNA的癌症早期检测领域具有显著的技术、产品和市场优势，是该领域 的全球领导者之一。光大证券国际此前指出，全球癌症筛查市场空间广阔，行业进入壁垒高。 GASTROClear™是全球市场上唯一一款获批准进行胃癌筛查的分子诊断IVD产品，按2023年收益计，在 东南亚基于miRNA的液体活检胃癌筛查市场上拥有最大的市场份额（市场份额为66.3%）。 智通财经获悉，MIRXES-B(02629)涨近9%，高见40.66港元创上市新高，较招股价23.3港元已涨超七 成。截至发稿，涨8.96%，报40.62港元，成交额1666.18万港元。 公开资料显示，Mirxes觅瑞是一家以新加坡为总部的RNA生物科技公司，致力于开发及商业化针对癌症 及其他疾病早期筛查的精准、无创、可负担的血液miRNA检测。公司旗舰产品GASTROClear™/觅小卫 ™是一款基于血液miRNA的胃癌筛查分子检测试剂盒，已在包括新加坡及欧盟的多国获批，并取得美 国FDA突破性医疗器械认证。觅小卫™在中国已经完成了一项样本规模为9,472人的前瞻性临床试验， 目前正在注册申请中。 ...

Core Viewpoint - Mirxes-B (02629) has seen a significant increase in stock price, reaching a new high of 40.66 HKD, which is over 70% higher than its IPO price of 23.3 HKD [1] Company Overview - Mirxes is a Singapore-based RNA biotechnology company focused on developing and commercializing precise, non-invasive, and affordable blood miRNA tests for early cancer and disease screening [1] - The flagship product, GASTROClear, is a blood miRNA-based molecular diagnostic kit for gastric cancer screening, approved in multiple countries including Singapore and the EU, and has received breakthrough medical device certification from the FDA in the US [1] - GASTROClear has completed a prospective clinical trial with a sample size of 9,472 in China and is currently in the registration application process [1] Market Position - Guoyuan International believes that the company has significant technological, product, and market advantages in the field of miRNA-based early cancer detection, positioning it as one of the global leaders in this sector [1] - Everbright Securities International previously noted the vast market potential for global cancer screening, highlighting high industry entry barriers [1] - GASTROClear is the only approved molecular diagnostic IVD product for gastric cancer screening in the global market, holding the largest market share (66.3%) in the Southeast Asian miRNA-based liquid biopsy gastric cancer screening market as of 2023 [1]

公开资料显示，Mirxes觅瑞是一家以新加坡为总部的RNA生物科技公司，致力于开发及商业化针对癌症 及其他疾病早期筛查的精准、无创、可负担的血液miRNA检测。公司旗舰产品GASTROClear™/觅小卫 ™是一款基于血液miRNA的胃癌筛查分子检测试剂盒，已在包括新加坡及欧盟的多国获批，并取得美 国FDA突破性医疗器械认证。觅小卫™在中国已经完成了一项样本规模为9,472人的前瞻性临床试验， 目前正在注册申请中。 国元国际认为，公司在基于miRNA的癌症早期检测领域具有显著的技术、产品和市场优势，是该领域 的全球领导者之一。光大证券国际此前指出，全球癌症筛查市场空间广阔，行业进入壁垒高。 GASTROClear™是全球市场上唯一一款获批准进行胃癌筛查的分子诊断IVD产品，按2023年收益计，在 东南亚基于miRNA的液体活检胃癌筛查市场上拥有最大的市场份额（市场份额为66.3%）。 智通财经APP获悉，MIRXES-B(02629)涨近9%，高见40.66港元创上市新高，较招股价23.3港元已涨超 七成。截至发稿，涨8.96%，报40.62港元，成交额1666.18万港元。 ...

格隆汇8月13日丨MIRXES-B(02629.HK)公布，公司将于2025年8月25日召开董事会会议，以（其中包 括）审议及通过集团截至2025年6月30日止六个月的中期业绩及其发布。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或依 賴該等內容而引致的任何損失承擔任何責任。 （股份代號：2629） 董事會召開日期 Mirxes Holding Company Limited（「本公司」）董事（「董事」）會（「董事會」）謹此宣 佈，謹定於2025年8月25日（星期一）舉行董事會會議，藉以（其中包括）考慮及 通過本公司及其附屬公司截至2025年6月30日止六個月的中期業績以供發佈， 以及處理任何其他事項。 承董事會命 Mirxes Holding Company Limited （ 於 開 曼 群 島 註 冊 成 立 的 有 限 責 任 公 司 ） Mirxes Holding Company Limited 執行董事兼首席執行官 周礪寒博士 香港，2025年8月13日 於本公告日期，董事會包括(i)執行董事周礪寒博士、鄒瑞陽博士及何豪傑先生；(ii)非執行董 事朱興奮博士、樂貝林博士及柳達先生；及(iii)獨立非執行董事林倩麗博士、方曉先生及馬 露玲女士。 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: Mirxes Holding Company Limited (於開曼群島註冊成立的有限責任公司) 呈交日期: 2025年8月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02629 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | USD | | 0.00001 USD | | 100,000 | | 增加 / 減少 (-) | | | | | | USD | | | | 本月底結存 | | | 10,000,000,000 | USD | | 0.00001 USD | ...

Core Viewpoint - The Hong Kong stock market is experiencing an unprecedented capital boom in the biotechnology sector, with multiple pharmaceutical companies rushing to list, making it a strategic high ground for industry capitalization [1][2]. Group 1: Industry Capitalization Process - The IPO wave is intensifying, with three biopharmaceutical companies—Hengrui Medicine, Mirui, and PegBio—successfully listing on the Hong Kong stock exchange between May 23 and 27, 2023 [2]. - Hengrui Medicine's total market capitalization has surpassed 360 billion yuan, establishing it as an industry benchmark [2]. - Numerous companies, including AI drug leader Insilico Medicine and immunotherapy firm Kewen Pharma, are currently advancing their IPO processes in Hong Kong [2]. Group 2: Policy and Capital Drivers - Recent policy relaxations have facilitated the listing of unprofitable biotech companies on the Hong Kong stock exchange, a first among major global capital markets [3]. - A fast-track listing channel for A-share companies with a market value of over 10 billion yuan will be introduced in October 2024, significantly improving listing efficiency [3]. - The tightening of A-share IPO reviews and geopolitical uncertainties affecting the U.S. market have made Hong Kong a more attractive financing destination due to its high degree of internationalization and capital flow freedom [3]. Group 3: Globalization Strategy - The surge in Hong Kong listings reflects a deepening globalization strategy within China's biopharmaceutical industry [4]. - The Hong Kong market serves as an international capital hub, providing a platform for direct dialogue between pharmaceutical companies and international investors, with foreign ownership in the healthcare sector reaching 34% in Q1 2025 [4]. - Listing in Hong Kong helps companies establish international market recognition, facilitating overseas clinical trials and patent negotiations, as evidenced by Junshi Biosciences' record overseas licensing deal for its PD-1 antibody [4]. Conclusion - The continuous policy iterations by the Hong Kong Stock Exchange have aligned with the capital needs of the industry, enabling pharmaceutical companies to expand their global resource allocation and participate in international competition [5]. - The current influx of companies into the Hong Kong market represents not only an expansion of financing channels but also a strategic pivot for Chinese innovative pharmaceutical firms aiming to secure a position in the global biopharmaceutical landscape [5].